Could GLP-1 medications be the missing piece in treating inflammatory skin disease? In this episode of Science is Skin, Dr. Ted Lain sits down with Dr. Lindsey Bordone — former Columbia University associate professor of dermatology, now in private practice at Bordone Dermatology in Scottsdale, Arizona — for a deep dive into metabolic disease and the skin.
Dr. Bordone was among the first dermatologists to prescribe GLP-1 agonists for her patients, and in this conversation she explains exactly why. From the link between hyperinsulinemia and chronic inflammation to the visible skin signs of insulin resistance — skin tags, acanthosis nigricans, forearm hair loss — she makes the case that dermatologists are uniquely positioned to catch metabolic disease before any other specialty.
Dr. Bordone walks through how she uses tirzepatide (Mounjaro/Zepbound), semaglutide (Ozempic/Wegovy), and the emerging triple-G drug retatrutide, including her lab protocols, dosing philosophy, how to manage GI side effects, and the surprising interaction between GLP-1s and estrogen therapy.
In this episode:
Resources mentioned:
Enjoyed this episode? Share it with a colleague and leave us a five-star review. Subscribe so you never miss an episode of Science is Skin.
To watch this and other episodes, be sure to check out our YouTube page
DISCLAIMER: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment.

Roflumilast Cream for Toddler Eczema, Psoriasis & Seborrheic Dermatitis
21:56

Hair Loss Treatments: Dr. Nicole Rogers on What Actually Works
32:57

Clinical Trials in Dermatology: Insider Tips from Top Researchers
28:32